History

Mira Dx was formed in February 2008 by researchers at Yale University to develop and bring to market gene-based laboratory tests based on sophisticated, ground-breaking genomic research conducted on miRNAs and the 3’UTR referred to as "miRNA genetics". This research is combined with active clinical evaluation of the findings.  The Company is applying miRNA discoveries to develop molecular diagnostics, which will provide individualized information on the likelihood of disease occurrence and response to certain types of therapy. These diagnostic technologies will generate information that healthcare providers and patients will use in making prevention and  treatment decisions.